Alliance Pharma plc
Alliance Pharma plc, a holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated i… Read more
Market Cap & Net Worth: Alliance Pharma plc (APH)
Alliance Pharma plc (LSE:APH) has a market capitalization of $4.26 Million (GBX34.97 Billion) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #42601 globally and #663 in its home market, demonstrating a 0.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alliance Pharma plc's stock price GBX64.70 by its total outstanding shares 540566016 (540.57 Million).
Alliance Pharma plc Market Cap History: 2015 to 2025
Alliance Pharma plc's market capitalization history from 2015 to 2025. Data shows growth from $2.54 Million to $4.26 Million (2.77% CAGR).
Index Memberships
Alliance Pharma plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$41.09 Million | 0.10% | #26 of 722 |
Weight: Alliance Pharma plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alliance Pharma plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alliance Pharma plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Alliance Pharma plc's market cap is 0.02 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.54 Million | $48.34 Million | $12.69 Million | 0.05x | 0.20x |
| 2016 | $2.79 Million | $97.49 Million | $18.09 Million | 0.03x | 0.15x |
| 2017 | $3.99 Million | $103.31 Million | $28.91 Million | 0.04x | 0.14x |
| 2018 | $4.04 Million | $118.21 Million | $18.36 Million | 0.03x | 0.22x |
| 2019 | $5.18 Million | $135.64 Million | $25.01 Million | 0.04x | 0.21x |
| 2020 | $5.43 Million | $129.80 Million | $8.03 Million | 0.04x | 0.68x |
| 2021 | $6.85 Million | $163.21 Million | $7.32 Million | 0.04x | 0.94x |
| 2022 | $3.41 Million | $167.42 Million | -$21.21 Million | 0.02x | N/A |
| 2023 | $2.66 Million | $180.68 Million | -$33.14 Million | 0.01x | N/A |
| 2024 | $3.01 Million | $178.84 Million | -$10.73 Million | 0.02x | N/A |
Competitor Companies of APH by Market Capitalization
Companies near Alliance Pharma plc in the global market cap rankings as of March 18, 2026.
Key companies related to Alliance Pharma plc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Alliance Pharma plc Historical Marketcap From 2015 to 2025
Between 2015 and today, Alliance Pharma plc's market cap moved from $2.54 Million to $ 4.26 Million, with a yearly change of 2.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | GBX4.26 Million | +41.42% |
| 2024 | GBX3.01 Million | +12.96% |
| 2023 | GBX2.66 Million | -21.88% |
| 2022 | GBX3.41 Million | -50.25% |
| 2021 | GBX6.85 Million | +26.23% |
| 2020 | GBX5.43 Million | +4.89% |
| 2019 | GBX5.18 Million | +28.03% |
| 2018 | GBX4.04 Million | +1.43% |
| 2017 | GBX3.99 Million | +42.70% |
| 2016 | GBX2.79 Million | +10.17% |
| 2015 | GBX2.54 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Alliance Pharma plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.26 Million USD |
| MoneyControl | $4.26 Million USD |
| MarketWatch | $4.26 Million USD |
| marketcap.company | $4.26 Million USD |
| Reuters | $4.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.